<bill session="115" type="h" number="6801" updated="2023-01-11T13:41:33Z">
  <state datetime="2018-09-13">REFERRED</state>
  <status>
    <introduced datetime="2018-09-13"/>
  </status>
  <introduced datetime="2018-09-13"/>
  <titles>
    <title type="display">RaD Fund Act of 2018</title>
    <title type="official" as="introduced">To establish a Rare Disease Therapeutics Corporation to encourage the development of high-risk, high-return therapies for rare diseases, and for other purposes.</title>
    <title type="short" as="introduced">RaD Fund Act of 2018</title>
    <title type="short" as="introduced">Rare Disease Fund Act of 2018</title>
  </titles>
  <sponsor bioguide_id="V000130"/>
  <cosponsors>
    <cosponsor bioguide_id="P000608" joined="2018-09-13"/>
    <cosponsor bioguide_id="R000583" joined="2018-09-13"/>
  </cosponsors>
  <actions>
    <action datetime="2018-09-13">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-09-13" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Advisory bodies"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Health programs administration and funding"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Medical research"/>
    <term name="National Institutes of Health (NIH)"/>
    <term name="Research administration and funding"/>
    <term name="Research and development"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-20T20:32:00Z" status="Introduced in House">Rare Disease Fund Act of 2018 or the RaD Fund Act of 2018

This bill requires the Department of the Treasury to organize the Rare Disease Therapeutics Corporation to purchase rights to, fund the development of, and sell ownership interests in drugs, biological products, and medical devices for rare diseases.</summary>
</bill>
